Clinical Trial Search

Primary: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 — 8.14; -40.01; -30.14; -40.13 percent change — p=0.0000

Primary: Safety and Tolerability of RMJH-111b Compared to Placebo Based on Treatment Emergent Adverse Events (TEAEs) — 5; 1; 0; 0 Participants

Primary: Mean of the Change in Morphine Dosage (in mg) Required to Achieve 25% Reduction in Thermal Evoked Pain Responses Relative to Baseline (Pre-intervention) Placebo…

Primary: Maximum Number of Days With Asthma Symptoms Within 2 Weeks — 2.2; 2.7; 1.2; 2.1 days

Primary: Aortic Pulse Wave Velocity (PWV) — 9.90; 9.96; 7.62; 8.57 m/s — p=0.685

Primary: Percentage of Patients Alive and Free From Invasive Disease (IDFS) — 89.2; 89.8 percentage of patients

Primary: The Primary Safety Endpoint for This Study is the Incidence of Early-onset (Within 7 Days of the PEF Ablation Procedure) Primary Adverse Events (AEs). — 2.5 percentage…

Primary: How Satisfied Were Participants With Treatment? — 0; 1; 2; 2 Participants

Primary: Number of Subjects Considered a Clinical Cure at Day 8 — 91; 63 Participants

Primary: Effect of Pulse Train Length on Transcranial Motor Evoked Potentials (TcMEP) Area Under Total Intravenous Anesthesia (TIVA) and TIVA Plus 3% Desflurane — 2 Participants

Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD

Primary: Subjective Ratings for Comfort After Lens Insertion — 91; 93 units on a scale

Primary: Lens Fit Acceptance — 2.6; 3.1 units on a scale

Primary: Number of Patients That Adhere to the 2009 Syncope Guidelines (ESC2009) — 233 Participants

Primary: Rate of All-cause Readmissions — 0; 0 Participants